Skip to Main Content

Spotlight on... awareness weeks

Awareness weeks guide

Ovarian Cancer Awareness Month 2025

Ovarian Cancer Awareness Month

February 2025

Ovarian Cancer Awareness Month (OCAM) takes place throughout the month of February in Australia annually. It is an important advocacy and awareness month shining a spotlight on ovarian cancer and broadening the community’s knowledge of this poorly understood disease. Ovarian Cancer Research Foundation

UpToDate

Diagnosis

General

Screening

Treatment

Cochrane Library

Guidelines

Online resources

Reports

Articles

Prevention

Diagnosis and Screening

Research

Treatment

E-books

E-journals

__________________________________________________________________________________

Articles

Prevention

Breastfeeding’s protective role in alleviating ovarian cancer burden: a comprehensive review
Breastfeeding, an essential aspect of infant care, has garnered recognition beyond its immediate health benefits, revealing a profound and lasting impact on women’s health. Emerging research has unveiled a compelling relationship between breastfeeding and its enduring role in reducing the risk of ovarian cancer. This narrative review aims to comprehensively examine the lifelong impact of breastfeeding on ovarian cancer prevention, transcending infancy and delving into the mechanisms and implications for women’s health. Annals of medicine and society 5 March 2024

Current science and practice of surgical and non-surgical opportunities for ovarian cancer prevention
This evidence-based review provides a critical appraisal of the translational health research endeavors supporting ovarian cancer prevention in clinical practice. Clinical obstetrics and gynecology 1 December 2024

Exploring strategies to prevent and treat ovarian cancer in terms of oxidative stress and antioxidants
Studying oxidative stress in ovarian cancer is important for the prevention and treatment of ovarian cancer. Antioxidants, important markers of oxidative stress, might serve as one of the strategies for preventing and treating ovarian cancer. In this review, the authors discuss the complex relationship between oxidative stress and ovarian cancer, as well as the role and therapeutic potential of antioxidants in ovarian cancer, thus guiding future research and clinical interventions. Anitoxidants 20 January 2025

Most relevant genetic factors in ovarian cancer development
Ovarian cancer (OC) represents a significant challenge in the realm of gynecological cancers, characterized by poor survival rates and complex etiology. This review delves into the genetic, environmental, and hormonal factors underpinning OC development, shedding light on both well-established contributors and emerging influences. AIMS molecular science 2 January 2025

Ovarian cancer risk reduction by salpingectomy during non-gynaecological surgery: scoping review
Ovarian cancer is the leading cause of death among gynaecological cancers. The identification of the fallopian tube epithelium as the origin of most ovarian cancers introduces a novel prevention strategy by removing the fallopian tubes during an already indicated abdominal surgery for another reason, also known as an opportunistic salpingectomy. This preventive opportunity is evidence based, recommended and established at the time of gynaecologic surgery in many countries worldwide. To expand interest among surgeons in performing a salpingectomy during non-gynaecological surgery, the aim of this review is to identify knowledge gaps during those surgeries. BJS open 28 January 2025

Ovarian cancer prevention through opportunistic salpingectomy during abdominal surgeries: A cost-effectiveness modeling study
Based on this model, interdisciplinary implementation of opportunistic salpingectomy (OS) in any suitable abdominal surgeries could contribute to prevention of ovarian cancer and reduction of healthcare costs. Plos medicine 30 January 2025
__________________________________________________________________________________

Diagnosis and Screening

A review of deep learning models for early detection and diagnosis of ovarian cancer
This paper attempts to review the various deep learning (DL) models in ovarian cancer diagnosis, including detecting risk factors, analyzing genomic data sets, predicting disease progression, recurrence, and mortality rates, and identifying correlations and patterns. International research journal of multidisciplinary technovation 27 January 2025

Early diagnosis of ovarian cancer: A comprehensive review of the advances, challenges, and future directions
This review highlights the critical need for continued research and innovation to enhance early diagnosis, reduce mortality, and improve patient outcomes in ovarian cancer (OC) and posits personalized medicine, integrated emerging technologies, and targeted global initiatives and collaborative efforts, which address care access disparities and promote cost-effective, scalable screening strategies, as potential tools to combat OC. Diagnostics 7 February 2025

Multicenter study of ovarian cancer score for diagnosing ovarian cancer
Highlights

  • Ovarian Cancer Score (OCS) demonstrates high sensitivity and specificity in detecting epithelial ovarian cancer (EOC).
  • OCS outperformed CA125 in both sensitivity and specificity in detecting EOC.
  • OCS showed high sensitivity in early-stage EOC indicating its potential for early, non-invasive diagnosis.

Gynecologic Oncology  2 February 2025

Prevalence and prognostic significance of Sarcopenia in gynecologic oncology: A systematic review and meta-analysis
The meta-analysis revealed that the prevalence of sarcopenia in gynaecologic oncology patients was 38.8%. Subgroup analysis indicated that the prevalence of sarcopenia was higher among patients with endometrial cancer or ovarian cancer, those over 60 years of age, individuals with a body mass index (BMI) greater than 25 kg/m2, those diagnosed using the psoas muscle index (PMI) and patients assessed at the L4 vertebra. Overall survival (OS) was significantly lower in patients with gynaecologic tumours combined with sarcopenia compared to those with gynaecologic tumours alone. However, no significant differences were observed in progression-free survival (PFS), mortality or length of hospital stay. Sarcopenia has a high prevalence in gynaecologic oncology patients. Healthcare professionals should prioritize early screening and preventive measures for high-risk patients. Journal of cachexia, sarcopenia and muscle 2 February 2025

__________________________________________________________________________________

Research

Analysis of the global burden of ovarian cancer in adolescents
The disease burden of ovarian cancer among adolescents continues to rise globally, particularly in regions and countries with moderate to low economic development. Enhancing the equitable allocation of healthcare resources to facilitate early diagnosis and treatment is essential for future treatment and research strategies. International journal of gynecological cancer 8 January 2025

Borderline tumours of the ovary: A 37-year experience at a tertiary referral centre
This study describes important information correlating first surgical procedure and fertility-sparing surgery to recurrence and malignant transformation. For all borderline ovarian tumours (BOT) subtypes, fertility-preserving surgery increased the risk of recurrence and hysterectomy was not superior to removal of both ovaries. In mucinous tumours (MBOT), frozen section is of limited utility and the macroscopically normal appendix is very unlikely to be anything but benign, if MBOT is the true histologic diagnosis. Australian and New Zealand journal of obstetrics and gynaecology 21 October 2024

Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy in patients with ovarian cancer: A scoping review
Highlights

  • Exercise therapy has potential benefits for patients with ovarian cancer who have chemotherapy-induced peripheral neuropathy (CIPN).
  • Daily physical inactivity was associated with a higher incidence of CIPN.
  • Low skeletal muscle density was associated with CIPN.
  • Physical dysfunction was associated with CIPN.
  • Evidence on the effectiveness of exercise for CIPN is still limited and further research is needed.

Gynecologic oncology 12 December 2024

Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey
Findings indicate that there is a need to improve both access to and information about Homologous recombination deficiency (HRD) testing. Future oncology 15 January 2025

Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival—A prospective cohort study in Australia
Pre-diagnosis menopausal hormone therapy (MHT) use was associated with improved survival, particularly in high-grade serous carcinoma (HGSC). Among women ≤55 years, use of MHT following treatment was not associated with poorer survival for HGSC. Further large-scale studies are needed to understand menopause-specific health-related quality of life (HRQOL) issues in ovarian cancer. International journal of cancer 2 September 2024

Worldwide patterns and trends in ovarian cancer incidence by histological subtype: a population-based analysis from 1988 to 2017
Variations in global patterns and trends in OC incidence and its subtypes might be influenced by genetic and reproductive factors. Consequently, region-specific prevention strategies and ongoing surveillance are essential to mitigate the burden of OC. eClinicalMedicine 6 December 2024

__________________________________________________________________________________

Treatments

A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis
All included Poly(ADP-ribose) polymerase (PARP)  showed various degrees of benefit in survival outcomes and safety profile was acceptable for PSROC patients. Among them olaparib had the best performance in both efficacy and safety. Journal of ovarian research 30 January 2025

Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?
Highlights

  • Patients doing higher-intensity exercise during chemotherapy reported less fatigue and fewer treatment side-effects.
  • Higher-intensity exercise during chemotherapy was associated with less moderate-severe clinician-reported neurotoxicity.
  • Chemotherapy completion appeared better in higher-intensity exercisers, especially among those on 3-weekly regimens.
  • Sitting less during chemotherapy was associated with fewer side-effects, but not chemotherapy completion.
  • There was a suggestion higher-intensity exercise may improve survival in advanced disease patients having typical treatment.

Gynecologic Oncology 14 August 2024

Chemotherapy-induced alopecia in ovarian cancer: Incidence, mechanisms, and impact across treatment regimens
Chemotherapy-induced alopecia (CIA) is a common and distressing side effect of cancer treatment, significantly impacting patients’ self-esteem and quality of life. While chemotherapy is a cornerstone of ovarian cancer care, its impact on hair loss has not been comprehensively studied in this patient population. This review examines the frequency and severity of CIA associated with widely used chemotherapies, including taxanes and platinum-based agents, and evaluates factors such as drug combinations and dosing schedules that influence hair loss. By identifying patterns and potential strategies to minimize CIA, this study aims to improve patient quality of life without compromising the effectiveness of cancer treatments. These findings provide valuable insights for clinicians and their patients, fostering informed decision-making and encouraging further advancements in managing the adverse effects of cancer therapies. Cancers 26 January 2025

Controversies in the management of clear cell carcinoma of the uterus and ovary
This review emphasizes the necessity of international collaboration and the inclusion of diverse patient populations to address the challenges posed by clear cell carcinomas. By focusing on these controversies, the authors aim to stimulate further research and support more evidence-based, personalized approaches in the management of these rare but challenging cancers. International journal of gynecological cancer 31 January 2025

Predicting response to treatment and survival in advanced ovarian cancer using machine learning and radiomics: A systematic review
This is a systematic review of the published literature from January 1985 to December 2023 on the use of Machine learning and radiomics (ML/RM) in ovarian cancer. Cancers 21 January 2025

Probe-based confocal laser endomicroscopy intra-operative evaluation in ovarian cancer: definition of in vivo architectural patterns to determine resection strategies
These results suggest that pCLE is a promising intra-operative technique to assist surgeons in accurately detecting peritoneal metastases in patients with advanced epithelial ovarian cancer, enhancing surgical radicality while avoiding unnecessary resection. International journal of gynecological cancer 4 January 2025

Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer
The authors found that patients with epithelial ovarian cancer (EOC) who received niraparib, after platinum-based chemotherapy, lived about 11 months without their cancer worsening or dying and lived about 12 months without needing to take another treatment. Future oncology 17 January 2025

__________________________________________________________________________________

E-books

This is just a sample of the e-books the library subscribes to – you will need your library login

_________________________________________________________________________________

E-Journals

This is just a sample of the journals the library subscribes to – you will need your library login

__________________________________________________________________________________